Ilya Yuffa
Known title: SVP & President, LLY Int'lCIK: 0001826001
Associated companies
Transaction History
| LLY | ▼ Sell | Open Market | 2,500 | $2.9M | 6/10/2026 | View on chart |
| LLY | ▲ Buy | Grant | 4,163 | $4.3M | 2/9/2026 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 1,512 | $1.6M | 2/1/2026 | View on chart |
| LLY | ▲ Buy | Option Exercise | 3,394 | $0 | 2/1/2026 | View on chart |
| LLY | ▼ Sell | Open Market | 1,250 | $784K | 8/11/2025 | View on chart |
| LLY | ▼ Sell | Open Market | 1,250 | $937K | 5/14/2025 | View on chart |
| LLY | ▲ Buy | Grant | 7,123 | $6.2M | 2/10/2025 | View on chart |
| LLY | ▲ Buy | Option Exercise | 3,269 | $0 | 2/1/2025 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 1,434 | $1.2M | 2/1/2025 | View on chart |
| LLY | ▲ Buy | Grant | 4,790 | $3.5M | 2/12/2024 | View on chart |
| LLY | ▲ Buy | Option Exercise | 3,702 | $0 | 2/1/2024 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 1,664 | $1.1M | 2/1/2024 | View on chart |
| LLY | ▲ Buy | Grant | 1,350 | $466K | 2/10/2023 | View on chart |
| LLY | ▼ Sell | Open Market | 1,000 | $243K | 2/16/2022 | View on chart |
| LLY | ▼ Sell | Open Market | 1,000 | $237K | 2/15/2022 | View on chart |
| LLY | ▲ Buy | Grant | 3,275 | $797K | 2/9/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Eli Lilly gets EMA backing for Foundayo obesity pill
The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.
Eli Lilly gets EMA backing for Foundayo obesity pill. The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.